Singapore: +65-85097465 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Zimbabwe: +263-735539685, 773876488

          

Clinical Trial News

FDA approve new drug to treat high cholesterol

Repatha is the second in a class of drugs to be approved by the FDA that addresses how the liver performs in relation to the treatment of high cholesterol.

TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial

TiGenix NV, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, has announced that...

Pivotal global Phase III study data for Fycompa® (perampanel) in primary generalised tonic-clonic seizures now published in Neurology

Pivotal, global phase III study results for Fycompa® (perampanel) in primary generalised tonic-clonic (PGTC) seizures are published for the first time today in Neurology.

Drug leads to significant weight loss for people with type 2 diabetes

Researchers find a daily dose of the diabetes drug liraglutide may lead to substantial weight loss for people with type 2 diabetes who are overweight or obese.

'Female Viagra' approved by FDA

The FDA have approved the first ever drug to treat low sexual desire in premenopausal women. Flibanserin - brand name Addyi - will be available from mid-October.

Phase 3 results for investigational therapy ITCA 650 in type 2 diabetes

Intarcia Therapeutics, Inc. has announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage...

Moffitt Cancer Center seeks breast cancer survivors for genetic counseling study

Moffitt Cancer Center is looking for breast cancer survivors for a study evaluating the effectiveness of new educational materials about genetic counseling.

Results from B-YOND extension study reinforce long-term clinical profile of ALPROLIX for the treatment of hemophilia B

New clinical data support the long-term safety and efficacy of ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in people with severe hemophilia B treated for up to two years...



James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook